STAT+

Pharmalot Ed Silverman

STAT Plus: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricing

D.C. Diagnosis John Wilkerson

STAT Plus: A new attack on AMA’s billing codes

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more

Biotech Adam Feuerstein

STAT Plus: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease

Biotech Allison DeAngelis

STAT Plus: Johnson & Johnson advances IBD therapy, despite trial miss

Pharmalot Ed Silverman

STAT Plus: French regulator fines Novo and Lilly over weight loss ad campaigns

Health Care Inc. Newsletter Bob Herman

STAT Plus: Pump the brakes on AI, buddy; and deposition deadlock

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an abortion pill controversy, another UCB deal, and more news

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more

Biotech Andrew Joseph

STAT Plus: Her daughter Mila got a bespoke medicine. Now she’s starting a new biotech to make more

Health Associated Press

STAT Plus: OxyContin maker Purdue Pharma set to dissolve after judge approves its criminal sentence

Politics Lizzy Lawrence

STAT Plus: Katherine Szarama named acting director of FDA’s vaccines and biologics center

Health Elizabeth Cooney, Helen Branswell, and Katie Palmer

STAT Plus: In her own words: Surgeon general nominee Nicole Saphier expresses enthusiasm and caution for MAHA

The Readout LOUD Allison DeAngelis, Adam Feuerstein, and Elaine Chen

STAT Plus: Hair-raising trial results, and Servier’s M&A wishlist

Health tech Katie Palmer

STAT Plus: As artificial intelligence shows off diagnostic chops, scientists reckon with the way forward

Pharmalot Ed Silverman

STAT Plus: FDA wants to exclude weight loss drugs from a compounding list

Insurance Bob Herman

STAT Plus: DOJ, Elevance spar over access to top exec in Medicare Advantage fraud case

Health Tech Newsletter Mario Aguilar

STAT Plus: Hinge has a new FDA-cleared migraine device

Business Tara Bannow

STAT Plus: Cigna will exit ACA individual markets next year, adding to tumult for patients

D.C. Diagnosis John Wilkerson

STAT Plus: Democrats go hard on health care affordability

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Supreme Court hearing on ‘skinny labels,’ AstraZeneca U.K. expansion, and more

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: What does Akeso’s primo plenary spot say about its survival data?

Health Elizabeth Cooney

STAT Plus: New obesity tool aims to predict risk of 18 serious complications

Pharmalot Ed Silverman

STAT Plus: Supreme Court justices appear to signal ‘skinny labeling’ can survive

AI Prognosis Brittany Trang

STAT Plus: Why conversations around health AI may be evolving beyond hype

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and more

Lab Dish Paul Knoepfler

STAT Plus: Did Kennedy just stack the deck on FDA oversight of peptides?

Politics Tara Bannow

STAT Plus: Health system CEOs get off easy at Congressional hearing on affordability